COVID-19: spontaneous pneumomediastinum possible, indicating worsening illness

  • Zhou C, et al.
  • Lancet Infect Dis
  • 17 Mar 2020

  • curated by Liz Scherer
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Chinese clinicians report the occurrence of spontaneous pneumomediastinum in a 38-year-old patient with confirmed COVID-19.
  • While the precise mechanism of spontaneous pneumomediastinum is unknown, it may cause severe circulatory and respiratory damage.

Why this matters

  • Closely monitor occurrence in COVID-19 patients as it may signal worsening disease.

Key points

  • 38-year-old male admitted to Central Hospital of Wuhan with 1-day history of fever without dizziness, cough, headaches.
  • Presentation: temperature, 38.1°C; C-reactive protein, 0.56 mg/dL; elevated leukocytes (10,060 cells/µL) and neutrophils (7550 cells/µL). 
  • Chest CT: multiple ground-glass opacities in lower lobes bilaterally.
  • At day 10, and following antibacterial, antiviral, and corticosteroid treatment, Reverse transcription (RT)-PCR confirmed COVID-19 in sputum samples. 
  • On day 11, patient developed exertional angina with cardiac palpitations and respiratory wheezing.
  • Chest CT: multiple ground-glass opacities with bilateral parenchymal consolidation and interlobular septal thickening.
  • Spontaneous pneumomediastinum, subcutaneous emphysema were also observed.
  • Management comprised continued ribavirin daily for 14 days, with added supplemental oxygen, antibiotics, antitussives, and bronchodilators, theophylline (0.2 g/12 hours), ambroxol (45 mg/12 hours), cefoperazone-tazobactam (2 g/8 hours) intravenously plus recombinant human interferon α-1b by aerosol 3 times a day for 14 days.
  • At day 25, temperature, cough, breathing improved to normal, RT-PCR negative, chest CT: resolution of previous pneumomediastinum, reduced parenchymal consolidation.
  • Patient was discharged on day 30 with negative RT-PCR.